Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy Summary A study using single-cell spatial analysis with the Xenium platform investigated the effects of Read More
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy Summary Nanobody-based bispecific antibody engagers offer a promising avenue for cancer immunotherapy. These molecules combine the target specificity of nanobodies, small and stable antibody Read More
Noncanonical and mortality-defining toxicities of CAR T cell therapy Summary CAR T-cell therapy, while revolutionary, can trigger severe toxicities beyond the well-known cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). These less Read More
The microbiota in radiotherapy-induced cancer immunosurveillance Summary Radiotherapy (RT) can trigger anti-tumor immune responses, a process known as immunosurveillance. The gut microbiota plays a crucial role in modulating this process. RT-induced changes in the gut Read More
Metabolic reprogramming in colorectal cancer: a review of aerobic glycolysis and its therapeutic implications for targeted treatment strategies Summary Colorectal cancer (CRC) cells exhibit metabolic reprogramming, primarily through aerobic glycolysis, also known as the Warburg Read More
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study Summary A Turkish Oncology Group study investigated the prognostic and Read More
Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses Summary Genetically engineered CAR-T cells can be modified to secrete bispecific killer cell engagers (BiKEs) targeting both tumor-associated antigens and NK Read More
Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study Summary This phase II study explored the efficacy of adding sintilimab (an anti-PD-1 immunotherapy) Read More
IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma Summary Interferon-gamma (IFNγ) enhances the effectiveness of tyrosine kinase inhibitors (TKIs) in treating hepatocellular carcinoma (HCC) by mitigating protein Read More
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B Summary The DisTinGuish trial Part B investigated the combination of DKN-01, a DKK1 inhibitor, and tislelizumab, an anti-PD-1 antibody, as Read More
1 Million+ Views and Counting..!
It has been 7 years since it was launched in late July 2018, and it is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
